TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07444541: ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Sponsor: Anova Innovation Limited · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07444541 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07444541 Rescue Dossier →